Literature DB >> 31278444

A Novel Genes Signature Associated with the Progression of Polycystic Ovary Syndrome.

Dongyun He1, Li Liu1, Yang Wang2, Minjia Sheng3.   

Abstract

To identify genes involving in the pathogenesis of polycystic ovary syndrome (PCOS). In this study, the comprehensive analysis of GSE8157 was downloaded. Overlapping genes of differentially expressed genes (DEGs) were identified, and enrichment analysis for these genes was performed. A modular network of differentially expressed genes was constructed by weighted gene co-expression network analyses (WGCNA), and a total of 322 differentially expressed genes in 5 stable modules were screened. The correlations of genes of the stable modules in BioGRID 3.4, STRING 10.5, HPRD9 databases were screened, and the interaction network of 104 DEGs was constructed. In addition, some genes and the key words were searched in CTD. A total of 596 differentially expressed genes were screened, including 379 genes that were up-regulated in case group and down-regulated in control group and treat group, and 217 genes that were down-regulated in case group and up-regulated in control group and treat group. The differentially expressed genes were enriched in PPAR signaling pathway, Neuroactive ligand-receptor interaction, cAMP signaling pathway, of which pathways were involved in the cancer development. Finally, 7 important target genes were identified, such as APOC3 was interacted with pioglitazone, ADCY2 involved in cAMP signaling pathway, and the genes (C3AR1, HRH2, GRIA1, MLNR and TAAR2) involved in neuroactive ligand-receptor interaction. In addition, the important target genes were significantly differential expression. These results implied that the 7 important target genes were played an important role in the development and progression of PCOS. Our study implied that genes had played a key role in the development and progression of PCOS, the results showed that microarray can be use as a method for the discovery of new biomarkers and therapeutic targets for PCOS.

Entities:  

Keywords:  Interaction network analysis; Microarray; Polycystic ovary syndrome; WGCNA

Mesh:

Year:  2019        PMID: 31278444     DOI: 10.1007/s12253-019-00676-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  26 in total

1.  Gene ontology: tool for the unification of biology. The Gene Ontology Consortium.

Authors:  M Ashburner; C A Ball; J A Blake; D Botstein; H Butler; J M Cherry; A P Davis; K Dolinski; S S Dwight; J T Eppig; M A Harris; D P Hill; L Issel-Tarver; A Kasarskis; S Lewis; J C Matese; J E Richardson; M Ringwald; G M Rubin; G Sherlock
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

2.  DAVID: Database for Annotation, Visualization, and Integrated Discovery.

Authors:  Glynn Dennis; Brad T Sherman; Douglas A Hosack; Jun Yang; Wei Gao; H Clifford Lane; Richard A Lempicki
Journal:  Genome Biol       Date:  2003-04-03       Impact factor: 13.583

3.  Chemical-Induced Phenotypes at CTD Help Inform the Predisease State and Construct Adverse Outcome Pathways.

Authors:  Allan Peter Davis; Thomas C Wiegers; Jolene Wiegers; Robin J Johnson; Daniela Sciaky; Cynthia J Grondin; Carolyn J Mattingly
Journal:  Toxicol Sci       Date:  2018-09-01       Impact factor: 4.849

Review 4.  Insulin resistance in patients with polycystic ovary syndrome.

Authors:  Annika K Schröder; Sascha Tauchert; Olaf Ortmann; Klaus Diedrich; Jürgen M Weiss
Journal:  Ann Med       Date:  2004       Impact factor: 4.709

Review 5.  Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.

Authors:  J M Lord; I H K Flight; R J Norman
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 6.  Insulin-lowering agents in the management of polycystic ovary syndrome.

Authors:  Vincenzo De Leo; Antonio la Marca; Felice Petraglia
Journal:  Endocr Rev       Date:  2003-10       Impact factor: 19.871

7.  Gene Co-Expression Network Analysis for Identifying Modules and Functionally Enriched Pathways in Type 1 Diabetes.

Authors:  Ignacio Riquelme Medina; Zelmina Lubovac-Pilav
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

8.  KEGG: new perspectives on genomes, pathways, diseases and drugs.

Authors:  Minoru Kanehisa; Miho Furumichi; Mao Tanabe; Yoko Sato; Kanae Morishima
Journal:  Nucleic Acids Res       Date:  2016-11-28       Impact factor: 16.971

9.  Human Protein Reference Database--2009 update.

Authors:  T S Keshava Prasad; Renu Goel; Kumaran Kandasamy; Shivakumar Keerthikumar; Sameer Kumar; Suresh Mathivanan; Deepthi Telikicherla; Rajesh Raju; Beema Shafreen; Abhilash Venugopal; Lavanya Balakrishnan; Arivusudar Marimuthu; Sutopa Banerjee; Devi S Somanathan; Aimy Sebastian; Sandhya Rani; Somak Ray; C J Harrys Kishore; Sashi Kanth; Mukhtar Ahmed; Manoj K Kashyap; Riaz Mohmood; Y L Ramachandra; V Krishna; B Abdul Rahiman; Sujatha Mohan; Prathibha Ranganathan; Subhashri Ramabadran; Raghothama Chaerkady; Akhilesh Pandey
Journal:  Nucleic Acids Res       Date:  2008-11-06       Impact factor: 16.971

10.  Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome.

Authors:  Vibe Skov; Dorte Glintborg; Steen Knudsen; Qihua Tan; Thomas Jensen; Torben A Kruse; Henning Beck-Nielsen; Kurt Højlund
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

View more
  1 in total

1.  Exploring Molecular Mechanism of Huangqi in Treating Heart Failure Using Network Pharmacology.

Authors:  Yan-Gu Tao; Xiu-Fang Huang; Jun-Yan Wang; Meng-Ru Kang; Ling-Jun Wang; Shao-Xiang Xian
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-23       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.